Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18199897 | 1.00 | CES2 (0.53) | CES2KDM4EALDH1A1CRBN | |
| SCHEMBL23903712 | 1.00 | CES2 (0.53) | CES2KDM4EALDH1A1CRBN | |
| SCHEMBL10013211 | 0.83 | CES2 (0.49) | CES2KDM4EALDH1A1CRBN | |
| SCHEMBL16077505 | 0.79 | CES2 (0.42) | CES2KDM4EALDH1A1 | |
| SCHEMBL2762976 | 0.77 | CES2 (0.51) | CES2KDM4EALDH1A1 | |
| SCHEMBL23903709 | 0.74 | CES2 (0.33) | CES2 | |
| SCHEMBL9219881 | 0.74 | CES2 (0.33) | CES2 | |
| SCHEMBL3303780 | 0.72 | CES2 (0.47) | CES2 | |
| SCHEMBL16079422 | 0.69 | ALDH1A1 (0.49) | CES2ALDH1A1 | |
| SCHEMBL16079419 | 0.69 | CES2 (0.34) | CES2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220133616-A1 | Compositions, Methods and Uses for Treating Skin Aging | EVANS ROBIN JAMES (US) | 2022-05-05 | — | — | US | claimed |
| EP-0754445-B1 | Photostable cosmetic light screening compositions | HOFFMANN LA ROCHE (CH) | 2001-10-24 | — | — | EP | claimed |
| EP-0754445-A2 | Photostable cosmetic light screening compositions | GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) | 1997-01-22 | — | — | EP | claimed |
| EP-3244930-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIV SOUTHERN CALIFORNIA (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260083685-A1 | METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260069587-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2026-03-12 | — | — | US | disclosed |
| US-12514828-B2 | Methods of permeabilizing the blood brain barrier | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4656641-A2 | METHODS AND DEVICES FOR USING ISOPERILLYL ALCOHOL | University of Southern California (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250332262-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2025-10-30 | — | — | US | disclosed |
| US-12383621-B2 | Pharmaceutical compositions comprising POH derivatives | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250186472-A1 | COMBINATION OF POH AND REMDESIVIR FOR TREATMENT OF CNS INFECTIONS | Neonc Technologies, Inc. | 2025-06-12 | — | — | US | disclosed |
| US-20220054481-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | UNIVERSITY OF SOUTHERN CALIFORNIA | 2022-02-24 | — | — | US | disclosed |
| WO-2016180973-A1 | PYROLYTIC METHOD FOR THE PRODUCTION OF PARTICLES CONTAINING AT LEAST ONE METAL SPECIES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2016-11-17 | — | — | WO | disclosed |
| EP-2123264-A1 | Heterocyclic derivatives as abnormal cannabidiols agents for lowering intraocular pressure | Allergan, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2007127711-A2 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070249596-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249596-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2007-10-25 | — | — | US | disclosed |
| EP-0754445-B1 | Photostable cosmetic light screening compositions | HOFFMANN LA ROCHE (CH) | 2001-10-24 | — | — | EP | disclosed |
| EP-0754445-A2 | Photostable cosmetic light screening compositions | GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) | 1997-01-22 | — | — | EP | disclosed |
| EP-0754445-A2 | Photostable cosmetic light screening compositions | GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) | 1997-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249596-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | CNR2, CNR1, PTGIR | CES2 3575/4885KDM4E 1564/4885ALDH1A1 3297/4885 |
| US-12383621-B2 | Pharmaceutical compositions comprising POH derivatives | PDE3A, PDE3B, PDE5A | CES2 403/4885KDM4E 215/4885ALDH1A1 205/4885 |
| US-20220133616-A1 | Compositions, Methods and Uses for Treating Skin Aging | GLA, TERT, CUTA | CES2 1225/4885KDM4E 965/4885ALDH1A1 306/4885 |
| US-20250186472-A1 | COMBINATION OF POH AND REMDESIVIR FOR TREATMENT OF CNS INFECTIONS | CFH, AQP4, MAG | CES2 345/4885KDM4E 1282/4885ALDH1A1 2939/4885 |
| US-20220054481-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | PMP22, CHAT, REL | CES2 532/4885KDM4E 911/4885ALDH1A1 46/4885 |
| US-20260069587-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | GCDH, PLIN3, PRPH | CES2 87/4885KDM4E 1771/4885ALDH1A1 400/4885 |
| US-20250332262-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PDE3A, PDE3B, PDE5A | CES2 403/4885KDM4E 215/4885ALDH1A1 205/4885 |
| US-20260083685-A1 | METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER | CD4, EPCAM, ICOS | CES2 323/4885KDM4E 3878/4885ALDH1A1 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.